🍽️ sulfanilamide (antibiotic)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antibacterial Activity: Sulfanilamide belongs to the sulfonamide class of antibiotics, which inhibit the growth and replication of susceptible bacteria by interfering with the synthesis of folic acid, a crucial component for bacterial survival. It is effective against a wide range of gram-positive and gram-negative bacteria.

  2. Historical Use: Sulfanilamide was one of the first synthetic antibiotics developed in the 1930s and played a significant role in the treatment of various bacterial infections before the introduction of newer antibiotics. It was used to treat conditions such as urinary tract infections, respiratory tract infections, wound infections, and sexually transmitted infections.

  3. Topical Formulations: Sulfanilamide is available in various topical formulations, including creams, ointments, powders, and sprays. These formulations are applied directly to the skin or mucous membranes to treat localized bacterial infections, burns, wounds, and other dermatological conditions.

  4. Mechanism of Action: Sulfanilamide works by inhibiting the enzyme dihydropteroate synthase, which is involved in the synthesis of folic acid in bacteria. By blocking this enzyme, sulfanilamide disrupts the production of nucleic acids and proteins essential for bacterial growth and replication, ultimately leading to bacterial death.

  5. Adverse Effects: Sulfanilamide may cause adverse effects in some individuals, including allergic reactions, skin sensitivities, and dermatitis. Hypersensitivity reactions such as rash, itching, swelling, and hives may occur, particularly in individuals with a history of sulfonamide allergy. Severe allergic reactions, although rare, may manifest as anaphylaxis, a life-threatening emergency requiring immediate medical attention.

  6. Drug Interactions: Sulfanilamide may interact with other medications or compounds, including other antibiotics, diuretics, anticoagulants, and certain nonsteroidal anti-inflammatory drugs (NSAIDs). It is essential to consult with a healthcare professional before using sulfanilamide concurrently with other medications to avoid potential interactions or adverse effects.

  7. Regulatory Considerations: The use of sulfanilamide in medical practice is subject to regulations and guidelines established by regulatory authorities to ensure its safe and appropriate use. Healthcare professionals are responsible for prescribing sulfanilamide judiciously, taking into account factors such as the patient's medical history, allergy profile, and susceptibility of the infecting organism.

  8. Consultation with Healthcare Provider: Individuals requiring treatment with sulfanilamide should consult with a qualified healthcare provider for proper diagnosis, treatment recommendations, and monitoring of their condition. Healthcare providers can provide guidance on the appropriate use of sulfanilamide and monitor for any adverse effects or complications associated with its use.


Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of sulfanilamide (antibiotic) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by sulfanilamide (antibiotic)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.


Taxonomy Rank Effect Citations Notation
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Lacticaseibacillus genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lachnospira eligens species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
[Ruminococcus] gnavus species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of sulfanilamide (antibiotic) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.4 0.4
Allergic Rhinitis (Hay Fever) 0.1 0.1
Allergies 0.2 0.4 -1
Allergy to milk products 0.3 0 0
Alzheimer's disease 1.2 0.4 2
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.2 0.2 0
Ankylosing spondylitis 0.1 0.5 -4
Anorexia Nervosa 0.3 -0.3
Antiphospholipid syndrome (APS) 0 0
Asthma 0.1 -0.1
Atherosclerosis 0.4 0.4
Atrial fibrillation 0.3 0.1 2
Autism 0.8 0.8 0
Barrett esophagus cancer 0.3 0.3
benign prostatic hyperplasia 0 0
Bipolar Disorder 0.3 0.2 0.5
Brain Trauma 0.1 -0.1
Cancer (General) 0.4 -0.4
Carcinoma 0.3 0.3 0
Celiac Disease 0.4 0.3 0.33
Cerebral Palsy 0.3 -0.3
Chronic Fatigue Syndrome 1.3 0.4 2.25
Chronic Kidney Disease 0.1 0 0
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.3 0 0
Chronic Urticaria (Hives) 0.1 0.1 0
Coagulation / Micro clot triggering bacteria 0.1 0.2 -1
Colorectal Cancer 1.2 1.2
Constipation 0.4 0.4
Coronary artery disease 0.2 0.2
COVID-19 0.6 1 -0.67
Crohn's Disease 1.2 0.7 0.71
cystic fibrosis 0.1 0.1 0
deep vein thrombosis 0.1 0.2 -1
Depression 1.3 0.7 0.86
Eczema 0 0.1 0
Endometriosis 0.1 0.2 -1
Eosinophilic Esophagitis 0.3 0.3
Epilepsy 0.5 0.1 4
Fibromyalgia 0.1 -0.1
Functional constipation / chronic idiopathic constipation 0.8 0.2 3
gallstone disease (gsd) 0.2 0.3 -0.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 0.7
Generalized anxiety disorder 0.3 0.1 2
Graves' disease 0.1 0.1
Halitosis 0.3 0.3
Hashimoto's thyroiditis 0.1 0.1 0
Hidradenitis Suppurativa 0.3 0.3
Histamine Issues 0.3 0 0
hyperglycemia 0 0.1 0
hypertension (High Blood Pressure 0.3 0.2 0.5
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.1 -0.1
Inflammatory Bowel Disease 0.3 0.8 -1.67
Insomnia 0.1 0.1 0
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 0.3 0.4 -0.33
Liver Cirrhosis 0.5 0.3 0.67
Long COVID 0.7 0.9 -0.29
Low bone mineral density 0 0
Lung Cancer 0 0.2 0
Mast Cell Issues / mastitis 0 0.2 0
ME/CFS with IBS 0.1 -0.1
ME/CFS without IBS 0.1 0.1 0
Metabolic Syndrome 0.7 0.9 -0.29
Mood Disorders 1.5 0.7 1.14
Multiple Sclerosis 0.4 0.4 0
Multiple system atrophy (MSA) 0.2 -0.2
neuropathic pain 0.1 -0.1
Neuropathy (all types) 0 0
neuropsychiatric disorders (PANDAS, PANS) 0 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0 0.3 0
Obesity 0.3 0.9 -2
obsessive-compulsive disorder 0.9 0.1 8
Osteoarthritis 0.1 0.2 -1
Osteoporosis 0.3 0.1 2
Parkinson's Disease 0 0.6 0
Polycystic ovary syndrome 0.6 0.4 0.5
Psoriasis 0.4 0.1 3
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.8 0.5 0.6
Rosacea 0.2 0.2
Schizophrenia 0.3 0.2 0.5
scoliosis 0.2 -0.2
Sjögren syndrome 0 0.1 0
Sleep Apnea 0.4 0.1 3
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 0.3
Stress / posttraumatic stress disorder 0.4 0.1 3
Systemic Lupus Erythematosus 0.5 0.2 1.5
Tic Disorder 0.5 0.5
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 0.7 0.3 1.33
Type 2 Diabetes 1 1 0
Ulcerative colitis 0.3 0.4 -0.33
Unhealthy Ageing 1.3 1.3

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]